Nitrogen Containing (e.g., Anilides, Etc.) Patents (Class 514/166)
  • Patent number: 10532973
    Abstract: Disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2? angle: 11.0°±0.2°, 20.6°±0.2°, 25.1°±0.2°, 8.2°±0.2°, 16.5°±0.2°, 13.4°±0.2°, 25.4°±0.2°.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: January 14, 2020
    Assignee: Zhejiang Yuejia Pharmaceuticals Co., Ltd
    Inventor: Jing Zhang
  • Patent number: 10501471
    Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof and methods of using the same for treating cardiovascular diseases.
    Type: Grant
    Filed: June 2, 2019
    Date of Patent: December 10, 2019
    Inventor: John Frederick Schmedtje, Jr.
  • Patent number: 10485848
    Abstract: The invention relates to a mussel adhesive protein (MAP) and an application thereof in inhibiting catarrh, and specifically, to applications of a MAP or a product thereof in oral mucositis, rhinitis, otitis media, pharyngitis, laryngitis, bronchitis, esophagitis, gastritis, enteritis, cervicitis, endomyometritis, inflammation resulting from inhalation injury, and oral cavity cancer, nasopharyngeal cancer, carcinoma of middle ear, conjunctival cancer, laryngeal cancer, lung cancer, esophageal cancer, stomach cancer, bowel cancer, cervical cancer, endometrial cancer, and other cancers resulting from the inflammation. The MAP can inhibit symptoms such as flush, fever, swell, and pain owing to catarrh, facilitating healing, relieving itch and pain, and having broad applications in the fields of medicines, cosmetics, medical products, disinfection products, healthcare products, foods, and household goods.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: November 26, 2019
    Assignee: JIANGYIN BENGT I. SAMUELSSON INSTITUTE OF LIFE SCIENCE CO., LTD.
    Inventors: Min Gao, Bengt Ingemar Samuelsson
  • Patent number: 10238592
    Abstract: A liquid fragrance composition consisting essentially of: cyclohexylidene phenyl acetonitrile; and one or more ingredients selected from the group consisting of cyclohexyl salicylate, MEFROSOL™ (3-methyl-5-phenyl-pentan-1-ol), HEDIONE™ (methyl 2-(3-oxo-2-pentylcyclopentyl)acetate), diethyl phthalate, isopropyl myristate, amyl salicylate, iso-amyl salicylate, benzyl salicylate, iso-bornyl salicylate, cis-3 hexenyl salicylate, ethyl salicylate, iso-butyl salicylate, methyl salicylate and phenylethyl salicylate; and optionally one or more of 3-methyl-5-phenylpentan-1-ol (MEFROSOL™); an alcohol comprising more than 3 carbon atoms selected from the group consisting of benzyl alcohol, 1-hexanol, 1-heptanol, 1-octanol, cyclohexanol, cyclohexyl propanol, methyl phenyl carbinol, phenyl ethyl alcohol and dimethyl benzyl carbinol; or a glycol ether.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: March 26, 2019
    Assignee: GIVAUDAN S.A.
    Inventors: Jean-Pierre Bachmann, Felix Flachsmann, Roger Wilhelm Geiser, Matias Mueller, Christian Quellet
  • Patent number: 10150792
    Abstract: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 11, 2018
    Assignee: Synthonics, Inc.
    Inventors: John D. Price, Thomas Piccariello, Robert A. Oberlender, Michaela E. Mulhare, Scott B. Palmer
  • Patent number: 10029991
    Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: July 24, 2018
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang, Sanjay Awasthi
  • Patent number: 9995752
    Abstract: Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: June 12, 2018
    Assignees: Children's Hospital Medical Center, Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Lee A. Denson, Bruce C. Trapnell, Jan Däbritz
  • Patent number: 9949988
    Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: April 24, 2018
    Assignee: AntibioTx A/S
    Inventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
  • Patent number: 9907828
    Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: March 6, 2018
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Yvonne M. Janssen-Heininger, Vikas Anathy
  • Patent number: 9890111
    Abstract: The crystal structure at 2.16 ? resolution of the full-length bacterial bifunctional transglycosylase penicillin-binding protein 1b (PBP1b) from Escherichia coli, in complex with its inhibitor moenomycin, is provided. The atomic coordinates of the complex as well as the moenomycin binding site are provided. Three dimensional structures of amino acid residues involved in moenomycin binding and transglycosylation activity are identified. Binding site for peptidoglycan synthesis inhibitors comprising inhibitor-binding site comprises amino acid residues from at least one of transglycosylase (TG), UvrB domain 2 homolog (UB2H) and transmembrane (TM) domains of PBP1b are identified at an atomic level of resolution. Methods for rational drug design based on the atomic coordinates are provided. Methods for screening for antibiotics based on anisotropic binding assay and transglycosylase inhibitor assays are provided. Novel antibiotics based on the screening assays of the invention are disclosed.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: February 13, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Che Alex Ma, Ting-Jen Rachel Cheng, Wei-Chieh Cheng
  • Patent number: 9682050
    Abstract: Disclosed herein are methods for treating lactose intolerance, including compounds that may be specific or modulate PPAR? receptors.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: June 20, 2017
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 9670153
    Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.
    Type: Grant
    Filed: August 17, 2013
    Date of Patent: June 6, 2017
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9629818
    Abstract: The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for parenteral administration and its use in the treatment of pain.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 25, 2017
    Assignee: TORRENT PHARMACEUTICALS LTD.
    Inventors: Sunil Sadanand Nadkarni, Jaya Abraham, Kapil Khatri
  • Patent number: 9498461
    Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: November 22, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9434771
    Abstract: The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: September 6, 2016
    Assignee: The Johns Hopkins University
    Inventors: Xuhang Li, Heng Zhu
  • Patent number: 9333187
    Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: May 10, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9149439
    Abstract: A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: October 6, 2015
    Assignee: Sandoz AG
    Inventors: Ashish Anilbhai Patel, Suresh Palaniswamy, Pablo Davila
  • Patent number: 9084765
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: July 21, 2015
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Publication number: 20150148318
    Abstract: A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 ?M concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Publication number: 20150140133
    Abstract: A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or therapeutic agent. The temperature sensitive hydrogel may also contain a drug or a therapeutic agent, for example, a pain relieving drug, for a short-term controlled release. The temperature sensitive hydrogel is in liquid state at room temperature, but upon injection, shortly becomes gelatinous. This system is particularly suitable for treatment of diseases, disorders, or conditions, for example, tumors, discogenic back pain, or arthritis, warranting localized administration of a drug or a therapeutic agent. In addition, the specification provides a method for production of a drug- or therapeutic agent-containing microspheres.
    Type: Application
    Filed: December 4, 2014
    Publication date: May 21, 2015
    Inventor: Tae-Hong Lim
  • Publication number: 20150141384
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological degenerative disorders, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Alzheimer's disease, Lewy body disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Application
    Filed: June 23, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150105324
    Abstract: The invention described herein pertains to compositions and methods for treating PTSD and related diseases. In particular, the invention described herein pertains to compositions and methods for treating PTSD and related diseases by administering modulators of NMDA NR2-PSD95-nNOS signaling.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 16, 2015
    Inventors: Anantha Shekhar, Yvonne Lai
  • Publication number: 20150099723
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Application
    Filed: April 11, 2014
    Publication date: April 9, 2015
    Applicant: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. MILNE, Michael R. JIROUSEK, Jean E. Bemis, Jesse J. Smith
  • Publication number: 20150099724
    Abstract: The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
    Type: Application
    Filed: August 14, 2014
    Publication date: April 9, 2015
    Inventors: Luigi Anzalone, Frank J. Villani, Christopher A. Teleha, Penina Feibush, Barry Fegely
  • Patent number: 8993546
    Abstract: An anti-parasiticidal composition presented as a topical “pour-on” product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20% (v/v) of one or more alcohols, and optionally including a polymeric moiety selected from the group consisting of polyvinylpyrrolidone (PVP), polyoxypropylene/polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: March 31, 2015
    Assignee: Norbrook Laboratories Limited
    Inventors: William Blakely, Lillian Cromie
  • Publication number: 20150065469
    Abstract: Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 5, 2015
    Inventors: Juan Jose Marugan, Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Elma Aflaki, Steven Andrew Rogers, Frank John Schoenen
  • Publication number: 20150056275
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 26, 2015
    Applicant: SANTARUS, INC.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Publication number: 20140370083
    Abstract: A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed.
    Type: Application
    Filed: September 2, 2014
    Publication date: December 18, 2014
    Inventors: Emma Boyd, Deborah Leigh Caldwell, Catherine Coulter, Ryan Loughlin, Stephen McCullagh
  • Publication number: 20140335205
    Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and/or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract.
    Type: Application
    Filed: April 1, 2014
    Publication date: November 13, 2014
    Inventor: Jay Pravda
  • Publication number: 20140315834
    Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.
    Type: Application
    Filed: September 23, 2013
    Publication date: October 23, 2014
    Applicant: Medicon Pharmaceuticals, Inc.
    Inventor: Basil RIGAS
  • Patent number: 8865688
    Abstract: Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 21, 2014
    Assignee: Dr. Falk Pharma GmbH
    Inventor: William Forbes
  • Publication number: 20140309200
    Abstract: The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 16, 2014
    Inventors: Uday B. Kompella, Sarath Yandrapu, Ashish Thakur
  • Patent number: 8858992
    Abstract: The present invention is directed to a high drug formulation having desirable properties in terms of ease of manufacture and visual appearance as well as a sachet for the formulation.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: October 14, 2014
    Assignee: Ferring B.V.
    Inventor: Svenn Klüver Jepsen
  • Patent number: 8846972
    Abstract: The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: September 30, 2014
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Chi B. Vu, Jean E. Bemis, Michael R. Jirousek, Jill C. Milne, Jesse J. Smith
  • Publication number: 20140255322
    Abstract: A siloxane polymer base that is useful as an excipient for many variable materials that can be compounded into it. Also disclosed are a method for the preparation of such bases, and another method regarding the preparation of the base and actives.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Inventors: John D. Blizzard, Robert L. McKellar
  • Patent number: 8802145
    Abstract: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form a moistened, plasticized mass, frozen to below ?20° C., and the water sublimed in high vacuum. In this way solid dosage forms are obtained with a similar porous structure as usually result from freeze drying processes, but the process requires much less water, which means considerably less time and less energy.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: August 12, 2014
    Assignee: Pantec AG
    Inventor: Kurt Heinz Bauer
  • Publication number: 20140221323
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. MILNE, Michael R. JIROUSEK, Jean E. Bemis, Jesse J. Smith
  • Publication number: 20140193492
    Abstract: The present invention concerns a new method of preparing granules comprising 5-aminosalicylic acid and a new method of preparing a pharmaceutical composition for the treatment of ulcerative colitis or Crohn's disease by oral administration comprising as active ingredient 5-aminosalicylic acid.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 10, 2014
    Applicant: Ferring B.V.
    Inventor: Svenn Kluver Jepsen
  • Patent number: 8765185
    Abstract: Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: July 1, 2014
    Assignee: Ferring B.V.
    Inventors: Carsten Hoeg-Moller, Crilles Casper Larsen, Jorgen Wittendorff, Birgitte Nissen, Kenneth Manby Pedersen, Tue Hansen, Helle Poulsen
  • Patent number: 8759327
    Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: June 24, 2014
    Assignees: The Regents of the University of Michigan, University of Maryland, Baltimore, Eastern Michigan University
    Inventors: Daniel A. Lawrence, Dudley Strickland, Jacqueline Cale, Enming J. Su, Cory Emal, Mark Warnock
  • Patent number: 8759325
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 24, 2014
    Assignee: The Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20140162986
    Abstract: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of thiol-containing compound transport.
    Type: Application
    Filed: February 13, 2014
    Publication date: June 12, 2014
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: Brian J. Day, Leonard W. Velsor
  • Publication number: 20140162989
    Abstract: The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to binary phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.
    Type: Application
    Filed: February 13, 2014
    Publication date: June 12, 2014
    Applicants: The Regents of the University of Michigan, University of South Florida
    Inventors: Michael J. Zaworotko, Nair Rodriguez-Hornedo, Brian Moulton
  • Patent number: 8735378
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: May 27, 2014
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
  • Patent number: 8735379
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: May 27, 2014
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
  • Publication number: 20140141075
    Abstract: A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed.
    Type: Application
    Filed: November 21, 2012
    Publication date: May 22, 2014
    Inventors: Emma Boyd, Deborah Leigh Caldwell, Catherine Coulter, Ryan Loughlin, Stephen McCullagh
  • Publication number: 20140141077
    Abstract: The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis.
    Type: Application
    Filed: July 2, 2012
    Publication date: May 22, 2014
    Applicant: Aihol Corporation
    Inventor: Shyh-Shyan Lin
  • Patent number: 8729293
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: May 20, 2014
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
  • Publication number: 20140073614
    Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.
    Type: Application
    Filed: May 22, 2013
    Publication date: March 13, 2014
    Applicant: Korea Ocean Research and Development Institute
    Inventors: Joung Han YIM, Il Chan KIM, Doc Kyu KIM, Se Jong HAN, Hyoung Seok LEE, Bhattarai HARI DATTA, Jung Eun KIM, Tai Kyoung KIM, Hyun Cheol OH, Dong-Gyu JO, Cheolsoon LEE, Keun-Sik KIM, Pyung Cheon LEE, Mi Ra PARK, Yu-Kyung PARK, Sung Jin KIM, Pil-Sung KANG, Heeyong PARK, Ha Ju PARK
  • Patent number: 8636996
    Abstract: The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: January 28, 2014
    Assignee: Emisphere Technologies, Inc
    Inventors: Halina Levchik, Shingai Majuru, Brahma Singh, Jamila Harris